Et tu, Brutus?

Perhaps the most controversial readout from ESMO22 this week was the phase 3 readout on Amgen’s pivotal trial for their KRAS G12C inhibitor in second line non-small cell lung cancer (NSCLC).

Instead of being an obvious shoo-in, quite a few surprising issues came to the fore – almost in a perfect storm fashion – acting to hobble the results in an unexpected fashion.

Here we review the issues and challenges facing sotorasib and also explore the potential impact on the field at large…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by